Lilly Endowment Inc., a director of Eli Lilly & Co, sold a total of 90,945 shares of common stock on February 21, 2025. This substantial sell-off could be indicative of a re-evaluation of the company's stock at its current price levels. Such a large sale may negatively impact the market, and investors should be cautious and monitor the company's future performance closely.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。